Anti-Cancer Drugs

Published by: Lippincott Williams & Wilkins  

People

  1. Fornier
    Fornier
  2. Kelsen
    Kelsen
  3. Foley
    Foley
  4. Kemeny
    Kemeny
  5. De Angelis
    De Angelis
  6. Ilson
    Ilson
  7. Norton
    Norton
  8. Saltz
    Saltz

Groups

  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (8)
  3. Breast Medicine Service (4)
  4. Gastrointestinal Oncology Service (4)
  5. Survivorship Research (4)
  6. Center for Pancreatic Cancer Research (3)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  8. Dermatology Service (1)
  9. Dermatology (1)
  10. Division of Subspecialty Medicine (1)
Search Within
  1. "Lippincott Williams & Wilkins"
Formats
  1. Journal Article (20)
  2. Conference Paper (2)
Groups
  1. Department of Medicine (9)
  2. Solid Tumor Oncology Division (8)
  3. Breast Medicine Service (4)
  4. Gastrointestinal Oncology Service (4)
  5. Survivorship Research (4)
  6. Center for Pancreatic Cancer Research (3)

More Groups

People
  1. Patrick Morris (4)
  2. David Kelsen (3)
  3. Monica Fornier (3)
  4. Daniel Martin (2)
  5. Kathleen Foley (2)
  6. Nancy Kemeny (2)

More People

Years
  1. 2016 (1)
  2. 2015 (1)
  3. 2014 (2)
  4. 2013 (1)
  5. 2012 (2)
  6. 2010 (1)

More Years

Publishers
  1. Lippincott Williams & Wilkins (22)

Results (22)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • MEK inhibitor treatment is effective in a patient with metastatic carcinoma of the ampulla of Vater with BRAF and NRAS mutations shown by next-generation sequencing
    Journal Article

    Tahover, E.; Bar Shalom, R.; Bogot, N.; Kelsen, D.; Gabizon, A.
    Anti-Cancer Drugs (2016)

    Fulltext@MSK | Save
  • Pharmacokinetics of low molecular weight heparin in patients with malignant tumors
    Journal Article

    Nasser, N. J.; Na'amad, M.; Weinberg, I.; Gabizon, A. A.
    Anti-Cancer Drugs (2015)

    Fulltext@MSK | Save
  • Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma
    Journal Article

    Bambury, R. M.; Morris, P. G.
    Anti-Cancer Drugs (2014)

    Fulltext@MSK | Save
  • Life-threatening dermatologic adverse events in oncology
    Journal Article

    Rosen, A. C.; Balagula, Y.; Raisch, D. W.; Garg, V.; Nardone, B.; Larsen, N.; Sorrell, J.; West, D. P.; Anadkat, M. J.; Lacouture, M. E.
    Anti-Cancer Drugs (2014)

    Fulltext@MSK | Save
  • Absence of pharmacokinetic drug-drug interaction of pertuzumab with trastuzumab and docetaxel
    Journal Article

    Cortes, J.; Swain, S. M.; Kudaba, I.; Hauschild, M.; Patel, T.; Grincuka, E.; Masuda, N.; McNally, V.; Ross, G.; Brewster, M.; more...
    Anti-Cancer Drugs (2013)

    Fulltext@MSK | Save
  • Recent advances in novel targeted therapies for HER2-positive breast cancer
    Journal Article

    Murphy, C. G.; Morris, P. G.
    Anti-Cancer Drugs (2012)

    Fulltext@MSK | Save
  • Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?
    Journal Article

    Morris, P. G.
    Anti-Cancer Drugs (2012)

    Fulltext@MSK | Save
  • Advances in therapy: Eribulin improves survival for metastatic breast cancer
    Journal Article

    Morris, P. G.
    Anti-Cancer Drugs (2010)

    Fulltext@MSK | Save
  • Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: Preliminary results of a feasibility-phase II study aimed at cardiotoxicity
    Journal Article

    Nisticò€, C.; Bria, E.; Vaccaro, V.; Cuppone, F.; Fornier, M.; Sperduti, I.; Carpino, A.; Lzzo, F.; Tropea, F.; Cognetti, F.; more...
    Anti-Cancer Drugs (2009)

    Fulltext@MSK | Save
  • Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: A phase II study
    Journal Article

    Nisticò€, C.; Bria, E.; Cuppone, F.; Fornier, M.; Sperduti, I.; Carpino, A.; Pace, A.; Cognetti, F.; Terzoli, E.
    Anti-Cancer Drugs (2007)

    Fulltext@MSK | Save

    • Anti-Cancer Drugs – authorized name for:

    Name ISSN / ISBN Publisher
    Anti-Cancer Drugs 09594973 Wolters Kluwer Health | Lippincott Williams & Wilkins
    Anti-Cancer Drugs 09594973 Wolters Kluwer Health | Lippincott Williams & Wilkins
    Anti-Cancer Drugs 0959-4973 Unknown
    Anti-Cancer Drugs 09594973 Lippincott Williams & Wilkins
    Anti-Cancer Drugs 0959-4973 Wolters Kluwer Health | Lippincott Williams & Wilkins
    Anti-Cancer Drugs 09594973 Unknown
    Anti-Cancer Drugs 09594973 Wolters Kluwer Health | Lippincott Williams & Wilkins
    Anti-Cancer Drugs 09594973 Lippincott Williams & Wilkins
    Anti-Cancer Drugs 0959-4973 Ovid Technologies, Inc.
    Anti-Cancer Drugs 09594973 Lippincott Williams & Wilkins
    Anti-Cancer Drugs 14735741 Unknown
    Anti-Cancer Drugs 0959-4973 Rapid Science Publishers
    Anti-Cancer Drugs 0959-4973 Lippincott Williams & Wilkins